CEL-SCI Corp banner
C

CEL-SCI Corp
AMEX:CVM

Watchlist Manager
CEL-SCI Corp
AMEX:CVM
Watchlist
Price: 3.53 USD -1.12% Market Closed
Market Cap: $29.9m

CEL-SCI Corp
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

CEL-SCI Corp
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
C
CEL-SCI Corp
AMEX:CVM
Inventory
$303.3k
CAGR 3-Years
-47%
CAGR 5-Years
-18%
CAGR 10-Years
-14%
Abbvie Inc
NYSE:ABBV
Inventory
$5B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Inventory
$1.8B
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Inventory
$6.2B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Inventory
$1.7B
CAGR 3-Years
54%
CAGR 5-Years
43%
CAGR 10-Years
40%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Inventory
$2.5B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
26%
No Stocks Found

CEL-SCI Corp
Glance View

Market Cap
29.9m USD
Industry
Biotechnology

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on activating the immune system to fight cancer and infectious diseases. The firm is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The firm is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.

CVM Intrinsic Value
32.18 USD
Undervaluation 89%
Intrinsic Value
Price
C

See Also

What is CEL-SCI Corp's Inventory?
Inventory
303.3k USD

Based on the financial report for Sep 30, 2025, CEL-SCI Corp's Inventory amounts to 303.3k USD.

What is CEL-SCI Corp's Inventory growth rate?
Inventory CAGR 10Y
-14%

Over the last year, the Inventory growth was -70%. The average annual Inventory growth rates for CEL-SCI Corp have been -47% over the past three years , -18% over the past five years , and -14% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett